Cellectar Biosciences, Inc.
CLRBNasdaq
$2.51
↓ -2.7%Jul 17 close · end-of-day
Price
1Y↓ -50.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.6M
Enterprise Value
$2.3M
P/E
—
P/S
—
P/B
3.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$20.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-624.9%
ROIC
—
Debt / Equity
—
Net Cash
$8.3M
Return 1Y
-49.5%
Company profile
Cellectar Biosciences, Inc. focuses on the discovery, development, and commercialization of drugs for cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
- CEO
- James V. Caruso
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- New Jersey
- Website
- cellectar.com
Management & directors
- Caruso James VChief Executive Officer
- Longcor JarrodChief Operating Officer
- Kolean Chad JChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
CLRB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.33↓ -69.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$15.3M | -$24.1M | -$28.8M | -$39.0M | -$51.8M | -$23.0M |
| Net income | -$15.1M | -$24.1M | -$31.8M | -$38.0M | -$44.6M | -$21.8M |
| Diluted EPS | -$1.84 | -$4.35 | -$4.51 | -$3.50 | -$41.89 | -$8.35 |
| Operating cash flow | -$13.9M | -$22.6M | -$25.2M | -$32.4M | -$47.6M | -$23.1M |
| Free cash flow | -$14.0M | -$22.7M | -$25.4M | -$33.2M | -$47.7M | -$23.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$13.7M | -$13.3M | -$12.7M | -$6.4M | -$6.0M | -$4.9M | -$5.7M | -$5.8M |
| Net income | -$919,371.00 | -$14.7M | -$2.4M | -$6.6M | -$5.4M | -$4.4M | -$5.3M | -$5.7M |
| Diluted EPS | -$5.43 | -$12.13 | -$23.42 | -$4.30 | -$3.39 | -$1.41 | $0.75 | -$1.33 |
| Operating cash flow | -$14.1M | -$9.2M | -$10.9M | -$9.4M | -$5.1M | -$4.3M | -$4.3M | -$4.8M |
| Free cash flow | -$14.2M | -$9.2M | -$11.0M | — | — | — | — | -$4.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 14, 2026
- 66d agoCellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...finance.yahoo.com
- 66d agoCellectar Biosciences, Inc. Q1 2026 Earnings Call Summaryapp.moby.co
- 67d agoCellectar (CLRB) Q1 2026 Earnings Transcriptfool.com
- 67d agoCellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updatesfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-07 | Longcor Jarrod· Chief Operating Officer | Buy | 8,680 | $2.88 | $24,998.40 | filing |
| 2026-05-07 | CARUSO JAMES V· Chief Executive Officer | Buy | 8,680 | $2.88 | $24,998.40 | filing |
| 2025-12-12 | NEIS JOHN | Sale | 198 | $3.70 | $731.99 | filing |
| 2025-07-02 | CARUSO JAMES V· Chief Executive Officer | Buy | 10,000 | $4.99 | $49,900.00 | filing |
| 2025-07-02 | Longcor Jarrod· Chief Operating Officer | Buy | 10,000 | $4.99 | $49,900.00 | filing |
| 2025-07-02 | Kolean Chad J· Chief Financial Officer | Buy | 5,000 | $4.99 | $24,950.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.